Cell Penetrating Peptides in Neuroscience

Cell-penetrating peptides (CPPs) are a highly specialized class of small peptides that possess the unique biochemical ability to rapidly cross cellular membranes.

CPPs have the incredible functional ability to actively transport complex molecules such as nucleic acids, large therapeutic proteins, pharmacological drugs, and diagnostic imaging agents directly into cells, making them an extremely important focus in disease pathology and diagnostic research. Of particular clinical interest is their immense potential impact on devastating conditions of the central nervous system (CNS), as specific CPPs have the highly unique ability to physically cross the restrictive blood-brain barrier alongside their conjugated molecules.

The Blood-Brain Barrier Challenge

The blood-brain barrier (BBB) is a vital protective mechanism of the CNS designed strictly to maintain delicate chemical homeostasis and protect the neural system from circulating toxins and pathogens. Structurally, the BBB is composed of four primary parts: a capillary basement membrane, highly specialized endothelial cells, pericytes, and astrocyte end-feet. These parts work dynamically together through the creation of impenetrable tight junctions and complex enzymatic barriers to meticulously keep the CNS healthy.

1. Brain Cancer

Gliomas are the most common type of primary cancer aggressively affecting the central nervous system. There are multiple subtypes of gliomas, with glioblastoma being by far the most highly aggressive and rapidly lethal. Current standard treatment of glioblastoma heavily involves difficult surgical resection, followed aggressively with systemic chemotherapy and radiation therapy. Complete, clean surgical resection is extremely difficult due to the highly invasive structural nature of glioblastoma and a severe lack of clean margins, which tragically almost always results in the rapid growth of secondary tumors. Thus, researchers are urgently looking for alternative, highly effective, and less physically invasive treatment options.

Multiple recent clinical studies have successfully evaluated the promising possibility of using cell-penetrating peptides to actively deliver genetic material, potent anticancer drugs, and engineered nanoparticles directly to glioblastoma cells. Cutting-edge studies actively involve pairings such as functional siRNA coupled with TAT peptides and highly toxic doxorubicin conjugated with penetratin. The unique peptide p28, surprisingly having intrinsic anticancer properties itself, has been brilliantly paired with diagnostic fluorescent labels to accurately determine surgical tumor margins, as well as paired directly with standard TMZ treatments to vastly increase overall clinical effectiveness.

2. Ischemic Stroke

Ischemic stroke is a devastating, rapid-onset condition in which the primary blood vessels in the brain become completely blocked by a traveling blood clot or ruptured plaque. This severe blocking instantly prevents oxygen and vital nutrients from successfully reaching brain tissue, causing massive cellular death (necrosis) within minutes. Stroke is a globally massive health concern, possessing an extremely high disability and mortality rate and possessing very few effective post-event treatments, aggressively driving researchers to rapidly look for novel neuroprotective treatment options.

Neuro-researchers have heavily explored the systemic use of cell-penetrating peptides in the immediate aftermath of ischemic stroke. Different targeted methods of treatment have been studied, explicitly including heavily reducing post-stroke neuroinflammation, addressing massive cellular excitotoxicity, and exploring widespread neuroprotection. Early clinical studies have yielded highly promising initial results for the rapid development of totally new therapeutic pharmacological treatments in these areas.

3. Neurodegenerative Diseases

Due directly to their highly unique functional ability to cross the blood-brain barrier, CPPs are being massively studied as a primary delivery mechanism for treating neurodegenerative diseases, such as Alzheimer’s Disease, Huntington’s Disease, and Parkinson’s Disease. While there are a few currently available treatments that strictly target symptom presentation, there are sadly no currently effective therapies for addressing the fundamental underlying causative disease pathology.

Pituitary adenylate cyclase-activating polypeptide (PACAP), an active cell-penetrating peptide, is of profound particular interest to modern scientists. Not only can this remarkable peptide successfully cross the blood-brain barrier, but the peptide itself natively possesses strong intrinsic neuroprotective properties. Low physiological levels of this peptide are clinically associated directly with severe cognitive decline in Alzheimer’s Disease. Targeted treatment with this peptide has actively shown incredibly strong neuroprotective effects directly against toxic Aβ-amyloid-42 oligomers and has successfully decreased the rapid progression of the disease in models. This peptide has also demonstrated powerful neuroprotective effects in Parkinson’s Disease models, actively preventing the aggressive degradation of neurons and drastically slowing overall cognitive decline.

Additionally, researchers are deeply studying the clinical impact of pairing specific cell-penetrating peptides with highly engineered nanoparticles. Nanotechnology offers massive pharmacological advantages, heavily including tunable particle size, shape, and the functional ability to precisely control the architecture and physical design of the delivery particles. These traits actively allow for vastly increased cellular uptake and heavily decreased off-target side effects due to extreme particle specificity.

4. References

1. Dotiwala AK, McCausland C, Samra NS. Anatomy, Head and Neck: Blood Brain Barrier. [Updated 2023 Apr 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519556/
2. Jagaran K, Singh M. Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer's and Parkinson's Diseases. Int J Mol Sci. 2021 Aug 23;22(16):9082. doi: 10.3390/ijms22169082. PMID: 34445784; PMCID: PMC8396516.
3. Kang, Y.C., Son, M., Kang, S. et al. Cell-penetrating artificial mitochondria-targeting peptide-conjugated metallothionein 1A alleviates mitochondrial damage in Parkinson’s disease models. Exp Mol Med 50, 1–13 (2018). https://doi.org/10.1038/s12276-018-0124-z
4. Keighron CN, Avazzadeh S, Goljanek-Whysall K, McDonagh B, Howard L, Ritter T, Quinlan LR. Extracellular Vesicles, Cell-Penetrating Peptides and miRNAs as Future Novel Therapeutic Interventions for Parkinson’s and Alzheimer’s Disease. Biomedicines. 2023; 11(3):728. https://doi.org/10.3390/biomedicines11030728
5. Li Zhang, Yanyu Zhang, Lingyu Tai, Kuan Jiang, Cao Xie, Zhuoquan Li, Yao-Zhong Lin, Gang Wei, Weiyue Lu, Weisan Pan, Functionalized cell nucleus-penetrating peptide combined with doxorubicin for synergistic treatment of glioma, Acta Biomaterialia, Volume 42, 2016, Pages 90-101. https://doi.org/10.1016/j.actbio.2016.06.031
6. Mander S, Naffouje SA, Gao J, Li W, Christov K, Green A, Bongarzone ER, Das Gupta TK, Yamada T. Tumor-targeting cell-penetrating peptide, p28, for glioblastoma imaging and therapy. Front Oncol. 2022 Jul 22;12:940001. doi: 10.3389/fonc.2022.940001. PMID: 35936749; PMCID: PMC9353713.
7. Mesfin FB, Al-Dhahir MA. Gliomas. [Updated 2023 May 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441874/
8. Raucher D. Tumor targeting peptides: novel therapeutic strategies in glioblastoma. Curr Opin Pharmacol. 2019 Aug;47:14-19. doi: 10.1016/j.coph.2019.01.006. Epub 2019 Feb 15. PMID: 30776641; PMCID: PMC7288394.
9. Wu Y, Angelova A. Recent Uses of Lipid Nanoparticles, Cell-Penetrating and Bioactive Peptides for the Development of Brain-Targeted Nanomedicines against Neurodegenerative Disorders. Nanomaterials. 2023; 13(23):3004. https://doi.org/10.3390/nano13233004
10. Zhang Y, Guo P, Ma Z, Lu P, Kebebe D, Liu Z. Combination of cell-penetrating peptides with nanomaterials for the potential therapeutics of central nervous system disorders: a review. J Nanobiotechnology. 2021 Aug 23;19(1):255. doi: 10.1186/s12951-021-01002-3. PMID: 34425832; PMCID: PMC8381574.